Vaxcyte, Inc.
PCVX
Rankning i aktier
#2079
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Aktiekurs
$64.29
Senast synkroniserad: 2026-10-19
Marknadsvärde
$9.86B
Förändring (1 dag)
1.05%
Förändring (1 år)
49.86%
Land
US
Handel Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
P/B-tal för Vaxcyte, Inc. (PCVX)
P/B-tal per October 2026 TTM: 3.54
Enligt Vaxcyte, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 3.54. I slutet av 2023 hade företaget ett P/B-tal på 4.92.
Historik för P/B-tal för Vaxcyte, Inc. från 2017 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 3.54 | 17.19% |
| 2024 | 3.02 | -38.58% |
| 2023 | 4.92 | 50.78% |
| 2022 | 3.26 | -24.99% |
| 2021 | 4.35 | 91.61% |
| 2020 | 2.27 | -343.31% |
| 2019 | -0.93 | -43.25% |
| 2018 | -1.64 | -154.55% |
| 2017 | 3.01 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | 76.63% |
US
|
|
| 13.2547 | 274.52% |
US
|
|
| 4.208 | 18.90% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 74.69% |
NL
|
